{
    "clinical_study": {
        "@rank": "13416", 
        "acronym": "STELLA", 
        "arm_group": [
            {
                "arm_group_label": "group 1", 
                "arm_group_type": "Experimental", 
                "description": "Cilostazol 50mg, Cilostzaol 100mg"
            }, 
            {
                "arm_group_label": "group 2", 
                "arm_group_type": "Placebo Comparator", 
                "description": "placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will be conducted in accordance with the local regulation of New Drug\n      Application. Overall duration of this trial will be 3 years after approval of KFDA.\n\n      Each subject will participate around 7 weeks, which include the 2 weeks Amlodipine run-in\n      period, 4 weeks double blind period and 1 week safety follow up period"
        }, 
        "brief_title": "A Therapeutic Confirmatory Study to Evaluate the Efficacy and Safety of Cilostazol in Subjects With Vasospastic Angina", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Vasospastic Angina", 
        "condition_browse": {
            "mesh_term": [
                "Angina Pectoris", 
                "Angina Pectoris, Variant"
            ]
        }, 
        "detailed_description": {
            "textblock": "A Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel group, Therapeutic\n      confirmatory Study.\n\n      The subject who has at least one episode of chest pain weekly and at least two episodes of\n      chest pain during last week despite Amlodipine 5mg qd taking during 2 weeks will have\n      treatment of Pletaal(Cilostazol) or Placebo for 4 weeks. Pletaal(Cilostazol) is taken 100mg\n      oral tablets bid during 2 weeks after dosing of Pletaal(Cilostazol) 50mg oral tablets bid\n      during 2 weeks. Placebo of Pletaal(Cilostazol) is used as the control medication."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Subjects must meet all of the following inclusion criteria to be eligible for enrollment\n        into the study :\n\n          1. Male or female 20 or over the age of 20 and under the age of 80\n\n          2. Angina episode(s) including at least one episode at rest before the screening,\n             diagnosis of vasospastic angina defined as at least one below at screening or within\n             3 months before the screening, and normal or insignificant (Diameter Stenosis <50%)\n             coronary artery disease by coronary angiography within 3 months before the screening.\n\n               -  A transient ST elevation of 0.1 mV or more, or an ST depression of 0.1 mV or\n                  more,  recorded in at least two contiguous leads on the 12-lead ECG with chest\n                  pain\n\n               -  Positive coronary spasm on coronary angiography in the ergonovine induced\n                  coronary spasm provocation test (Intracoronary (IC) or Intravenous (IV)\n                  Ergonovine provocation test) : The producing >90% narrowing of coronary lumen\n                  diameter with chest pain and ischemic ECG changes (A transient ST elevation of\n                  0.1 mV or more, or an ST depression of 0.1 mV or more, recorded in at least two\n                  contiguous leads on the 12-lead ECG)\n\n          3. At least one episode of chest pain weekly during the Amlodipine run in period for 2\n             weeks and at least two episodes of chest pain during last week of run-in period\n\n          4. Women must be postmenopausal (for at least 1 year), incapable of pregnancy, or, if\n             sexually active and capable of pregnancy, be practicing an acceptable method of birth\n             control (e.g., hormonal contraceptives, intrauterine device, male condom+spermicide,\n             female condom+spermicide, male partner sterilization)\n\n          5. Ability to provide own written informed consent after receiving a full explanation\n             for this study\n\n        Exclusion Criteria:\n\n          1. Currently taking or has taken Cilostazol within the last 3 month before the screening\n             visit.\n\n          2. Taking oral antiplatelet agents such as Aspirin, Clopidogrel or PDE3 inhibitors such\n             as Amrinone, Milrinone, Enoximone after Amlodipine run-in period.\n\n          3. Oral anticoagulants such as Warfarin within the last a month before the screening\n             visit.\n\n          4. Currently taking any of the following medications or has taken any of the following\n             medications within the last a week before the screening visit:\n\n               -  Other CCBs than Amlodipine\n\n               -  Beta-blocker, or Alpha-blocker\n\n               -  Oral Nitrate, Nicorandil, except Nitroglycerin sublingual PRN\n\n               -  Vitamin E preparations\n\n               -  Estrogens\n\n          5. History of Myocardial infarction or Myocardial infarction by vasospastic angina at\n             screening\n\n          6. History of life threatening vasospastic events such as ventricular tachycardia ,\n             ventricular fibrillation, or syncope\n\n          7. History of stroke, intracranial hemorrhage, or TIA\n\n          8. Hemorrhage (hemophilia, capillary fragility, intracranial hemorrhage, upper\n             gastrointestinal hemorrhage, urinary hemorrhage, hemoptysis, vitreous hemorrhage,\n             etc.) or such tendency (active peptic ulcer, hemorrhagic stroke within past 6 months,\n             a case hemorrhage is suspected by wound for surgery within 3 months, proliferative\n             diabetic retinopathy and uncontrolled hypertension)\n\n          9. History of clinically significant hypersensitivity to the substances of\n             dihydropyridine or nitrates including Cilostazol, Amlodipine, Nitroglycerin\n\n         10. Patients with severe aortic valve stenosis\n\n         11. History of shock\n\n         12. Hypotension of diastolic pressure < 90 mmHg at screening visit test\n\n         13. Patients with severe anemia of Hemoglobin \u2264 6.5 g/dl at screening visit test\n\n         14. History of glaucoma\n\n         15. ECG abnormality precluding interpretation of ST change at screening visit test\n\n         16. Congestive heart failure with less than 40% of left ventricular ejection fraction\n             within the last 3 month before the screening or screening period\n\n         17. Atrial fibrillation or valvular heart disease, more than moderate severity\n\n         18. Suspected or identified spasm of left main coronary artery, result of coronary\n             angiography or coronary angiography in the ergonovine induced coronary spasm\n             provocation test\n\n         19. History of Coronary artery bypass graft(CABG) or percutaneous coronary\n             intervention(PCI)\n\n         20. Tachycardia; Heart rate > 100 bpm, at Screening visit test via vital sign\n\n         21. Uncontrolled hypertension, defined as \u2265 160 mmHg systolic or \u2265 100 mmHg diastolic at\n             Screening visit test\n\n         22. Creatinine \u2265 1.5 mg/dL at screening visit test\n\n         23. Aspartate transaminase (AST) or alanine transaminase (ALT) > 3 times the upper limit\n             of normal (ULN) at screening visit test\n\n         24. Platelet < 100,000 mm3 at screening visit test\n\n         25. QT prolongation defined as baseline QTcB > 450 msec for males or QTcB > 470 msec for\n             females at Screening.\n\n         26. Women of childbearing potential who have positive pregnancy test result at screening\n\n         27. Women who are not using a reliable method of birth control, who are pregnant, or who\n             are breast-feeding\n\n         28. Drug compliance of Amlodipine < 80% during the Amlodipine run in period for 2 weeks\n\n         29. Otherwise judged by the investigator to be inappropriate for inclusion in the trial."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "79 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 17, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02087007", 
            "org_study_id": "021-KOA-1301i"
        }, 
        "intervention": {
            "arm_group_label": "group 1", 
            "description": "100mg oral tablets bid during 2 weeks after dosing of 50mg oral tablets bid during 2 weeks", 
            "intervention_name": "Cilostazol", 
            "intervention_type": "Drug", 
            "other_name": "Pletaal"
        }, 
        "intervention_browse": {
            "mesh_term": "Cilostazol"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Treatment for vasospastic angina", 
        "lastchanged_date": "March 9, 2014", 
        "location": {
            "contact": {
                "email": "junehongk@gmail.com", 
                "last_name": "Junghong Kim, M.D", 
                "phone": "055-360-1453"
            }, 
            "facility": {
                "address": {
                    "city": "Busan", 
                    "country": "Korea, Republic of", 
                    "zip": "626-770"
                }, 
                "name": "Yangsan Busan University Hospital"
            }, 
            "investigator": {
                "last_name": "JunHong Kim, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Therapeutic Confirmatory Study to Evaluate the Efficacy and Safety of Pletaal(Cilostazol) in Subjects With Vasospastic Angina", 
        "overall_contact": {
            "email": "junehongk@gmail.com", 
            "last_name": "Junghong Kim, M.D", 
            "phone": "010-8231-7171", 
            "phone_ext": "055-360-1453"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Ministry of Food and Drug Safety", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Change of the chest pain frequency on the final a week after IP dosing from a week before IP dosing", 
            "measure": "Chest Pain Frequency", 
            "safety_issue": "No", 
            "time_frame": "Baseline and Week 4"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02087007"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Percent change of the chest pain frequency on the final a week after IP dosing from a week before IP dosing", 
                "measure": "Percent change of the chest pain frequency", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 4"
            }, 
            {
                "description": "Proportion of subjects without chest pain on the final a week after IP dosing", 
                "measure": "Proportion of subjects without chest pain", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }, 
            {
                "description": "Change of the total pain intensity on the final a week after IP dosing from a week before IP dosing", 
                "measure": "total chest pain intensity", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 4"
            }, 
            {
                "description": "Change of the average pain intensity(the total pain intensity/the number of pain) on the final a week after IP dosing from a week before IP dosing", 
                "measure": "average pain intensity(the total pain intensity/the number of pain)", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 4"
            }, 
            {
                "description": "Change of the total nitroglycerin sublingual consumption of the final a week after IP dosing from a week before IP dosing", 
                "measure": "total nitroglycerin sublingual consumption", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 4"
            }
        ], 
        "source": "Korea Otsuka Pharmaceutical Co.,Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Korea Otsuka Pharmaceutical Co.,Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}